Structure Therapeutics grants options and RSUs

Structure Therapeutics Inc. Chief Development Officer Ashley Hall reported compensation-related equity grants.

Rhea-AI Filing Summary

Structure Therapeutics Inc. Chief Development Officer Ashley Hall reported compensation-related equity grants. Hall received an option to buy 59,073 ordinary shares at an exercise price of $16.82 per share, expiring on March 18, 2036, and now holds 59,073 derivative shares from this grant.

Hall was also awarded 47,706 restricted stock units, each representing one ordinary share, bringing direct ordinary share holdings to 155,187 shares after the award. The RSUs vest 1/4 each year on the anniversaries of March 1, 2026, while the option vests 1/4 on March 1, 2027 and monthly thereafter, subject to continued service.

Insider Trade Summary

Grant/Award: 106,779 shares

Grant/Award 2 txns

Insider Hall Ashley

Role Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	59,073	$0.00	$0.00
Grant/Award	Ordinary Shares	47,706	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 59,073 contracts (Direct); Ordinary Shares — 155,187 shares (Direct)

Footnotes (4)

1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
2. F2. Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates.
3. F3. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.
4. F4. 1/4th of the shares subject to the option shall vest March 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did GPCR executive Ashley Hall receive in this Form 4?

Ashley Hall received two equity awards: an option for 59,073 ordinary shares at a $16.82 exercise price and 47,706 restricted stock units. Both awards are compensation-related and vest over several years, subject to Hall’s continued service with Structure Therapeutics.

How many Structure Therapeutics (GPCR) shares does Ashley Hall hold after these grants?

After the reported grants, Ashley Hall directly holds 155,187 ordinary shares of Structure Therapeutics. This figure reflects the updated non-derivative share position following the 47,706-share restricted stock unit award disclosed in the Form 4 insider transaction report.

What are the vesting terms of Ashley Hall’s new GPCR stock options?

The option for 59,073 ordinary shares vests 1/4 on March 1, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter. Vesting is conditioned on Hall’s continued service through each vesting date, aligning incentives with long-term employment at Structure Therapeutics.

When do Ashley Hall’s restricted stock units in Structure Therapeutics vest?

The 47,706 restricted stock units vest in four equal annual installments. One quarter of the RSUs vests on each anniversary of March 1, 2026, provided Ashley Hall continues in service on each vesting date, gradually delivering ordinary shares over four years.

What is the exercise price and expiration date of Ashley Hall’s GPCR stock options?

The granted stock option has an exercise price of $16.82 per ordinary share and expires on March 18, 2036. The exercise price is based on the fair market value of Structure Therapeutics’ ordinary shares derived from the trading price of its American Depositary Shares.

How are Structure Therapeutics (GPCR) ordinary shares related to its ADSs in this filing?

The filing explains that Structure Therapeutics’ ordinary shares may be represented by American Depositary Shares. Each ADS represents three ordinary shares, providing investors a way to trade the company’s equity through ADSs while the underlying security remains the ordinary shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/23/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hall Ashley

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/19/2026		A(2)		47,706	A	$0	155,187	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$16.82(3)	03/19/2026		A		59,073		(4)	03/18/2036	Ordinary Shares(1)	59,073	$0	59,073	D

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

2. Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates.

3. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.

4. 1/4th of the shares subject to the option shall vest March 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

	/s/ Jun Yoon, Attorney-in-Fact	03/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)